Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug tame obesity caused by brain tumor treatment?

NCT ID NCT02860923

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether exenatide, a diabetes drug, plus lifestyle changes helps adults with severe weight gain after treatment for a rare brain tumor (craniopharyngioma). 42 adults aged 18-75 took either exenatide or a placebo for 6 months. The main goal was to see if they lost weight. The study also checked for side effects like nausea and injection-site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

42 people

The number who actually took part.

Started

Jan 2017

Finished

Sep 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * They are between 18 and 75 yrs. * They had been diagnosed with a craniopharyngioma treated by surgery and/or irradiation without sign of recurrence. * They have a BMI upper than 30kg/m² with intractable weight gain following therapy for craniopharyngioma. * They demonstrate at least one other endocrinopathy, as a marker of hypothalamic damage. * All pituitary deficiencies are correctly treated. * They gave their written, informed consent before the beginning of the study. Exclusion Criteria: * They have type 1 diabetes. * They have type 2 diabetes treated with insulin. * Acidocetosis. * Bariatric surgery * Previous personal history of thyroid or pancreatic cancer. * Hypercalcitoninemia. * They have been previously treated by GLP1 analogs. * Hypertriglyceridemia upper than 5g/l * They had previously demonstrated voluntary weight loss during the three previous months. * They are under the age of 18 years or over the age of 65 yrs. * They are maintained on medical treatment against obesity. * They are receiving supraphysiologic hydrocortisone therapy (upper than 30 mg/jour). * Their GH status change during the course of the study. * Exenatide is contraindicated. * Psychological and/or medical problems that would create difficulties for the patient to comply with the study protocol are present.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Craniopharyngiomas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired hypothalamic obesity craniopharyngioma Sexual Infantilism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Craniopharyngiomas Hypothalamic obesity

Contacts and locations

Locations

  • APHM

    Marseille, France

  • CHU d'Angers

    Angers, France

  • CHU de Brest

    Brest, France

  • CHU de Grenoble

    Grenoble, France

  • CHU de Lyon

    Lyon, France

  • CHU de Toulouse

    Toulouse, France

  • Hôpital Bicêtre

    Paris, France

  • Hôpital Cochin

    Paris, France

  • Hôpital Européen Georges Pompidou

    Paris, France

  • Hôpital Haut-Lévêque

    Pessac, France

  • Hôpital Pitié Salpétrière (APHP)

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.